Drug treatment for multidrug-resistant Acinetobacter baumannii infections.

Abstract

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging pathogen in healthcare settings, where it causes infections that include bacteremia, pneumonia, meningitis, and urinary tract and wound infections. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to the carbapenems. Other therapeutic options include sulbactam, aminoglycosides, polymixyns and tigecycline. The discovery of new therapies coupled with the development of controlled clinical trial antibiotic testing combinations and the prevention of transmission of MDR Acinetobacter infection are essential to face this important hospital problem.

• Authors: Matteo Bassetti, Elda Righi, Silvano Esposito, Nicola Petrosillo, Laura Nicolini
• Journal: Future microbiology (Future Microbiol) Vol. 3 Issue 6 Pg. 649-60 (Dec 2008) ISSN: 1746-0921 [Electronic] England
• PMID: 19072182 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents

Topics

• Acinetobacter Infections (drug therapy)
• Acinetobacter baumannii (drug effects)
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Cross Infection (drug therapy)
• Drug Resistance, Multiple, Bacterial
• Humans